Circular Genomics is collaborating with ophthalmic imaging startup Vitazi.AI to clinically validate a retinal-scan “oculomics” approach alongside its circular RNA biomarker platform for early Alzheimer’s screening. The company described its circRNA-based CircPATH platform as complementing existing assays that are sensitive but less specific. Separate from the device and biomarker validation efforts, Alzheimer’s research consortia are also scaling proteomics and imaging data—such as a large plasma proteomic effort using Alamar—to improve detection of Alzheimer’s and other neurodegenerative proteinopathies and accelerate clinical trial enrollment.